Nazzareno Galiè
A5065469571- Pulmonary Hypertension Research and Treatments
- Cardiovascular Issues in Pregnancy
- Cardiovascular Function and Risk Factors
- Vascular Anomalies and Treatments
- Heart Failure Treatment and Management
- Cardiac tumors and thrombi
- Venous Thromboembolism Diagnosis and Management
- Cardiac Imaging and Diagnostics
- Liver Disease and Transplantation
- Congenital Heart Disease Studies
- Acute Myocardial Infarction Research
- Atrial Fibrillation Management and Outcomes
- Cardiac Valve Diseases and Treatments
- Cardiac Structural Anomalies and Repair
- Cardiac Arrhythmias and Treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cardiomyopathy and Myosin Studies
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cardiovascular Effects of Exercise
- Coronary Interventions and Diagnostics
- Peptidase Inhibition and Analysis
- Cardiac pacing and defibrillation studies
- Advanced MRI Techniques and Applications
- Cardiac electrophysiology and arrhythmias
- Acute Ischemic Stroke Management
University of Bologna
2016-2025
Policlinico S.Orsola-Malpighi
2014-2025
Azienda USL di Bologna
2011-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2021-2024
ERN GUARD-Heart
2022-2024
Istituto delle Scienze Neurologiche di Bologna
2023
Ospedale Maggiore
2023
Okayama Medical Center
2022
National Hospital Organization
2022
St Vincent's Hospital Sydney
2021
The ESC/ERS Guidelines represent the views of ESC and ERS were produced after careful consideration scientific medical knowledge evidence available at time their publication.The are not responsible in event any contradiction, discrepancy and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies.Health professionals encouraged take fully into account when exercising...
The ESC Guidelines represent the views of and were arrived at after careful consideration available evidence time they written.Health professionals are encouraged to take them fully into account when exercising their clinical judgement.The guidelines do not, however, override individual responsibility health make appropriate decisions in circumstances patients, consultation with that patient, where necessary patient's guardian or carer.It is also professional's verify rules regulations...
Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing best management strategies for an individual patient a given condition. their recommendations should facilitate decision making daily practice. However, final decisions concerning must be made by responsible professional(s) consultation caregiver as appropriate.
The ESC Guidelines represent the views of and were produced after careful consideration scientific medical knowledge evidence available at time their publication.The is not responsible in event any contradiction, discrepancy and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies.Health professionals are encouraged take fully into account when exercising clinical...
Non-thrombotic PE does not represent a distinct clinical syndrome. It may be due to variety of embolic materials and result in wide spectrum presentations, making the diagnosis difficult. With exception severe air fat embolism, haemodynamic consequences non-thrombotic emboli are usually mild. Treatment is mostly supportive but differ according type material severity.
Endothelin-1 is a potent vasoconstrictor and smooth-muscle mitogen. In preliminary study, the orally administered dual endothelin-receptor antagonist bosentan improved exercise capacity cardiopulmonary hemodynamics in patients with pulmonary arterial hypertension. The present trial investigated effect of on larger number compared two doses.
Guidelines summarize and evaluate all available evidence on a particular issue at the time of writing process, with aim assisting health professionals in selecting best management strategies for an individual patient given condition, taking into account impact outcome, as well risk–benefit ratio diagnostic or therapeutic means. recommendations should help to make decisions their daily practice. However, final concerning must be made by responsible professional(s) consultation caregiver appropriate.
The ESC Guidelines represent the views of and were produced after careful consideration scientific medical knowledge evidence available at time their publication.The is not responsible in event any contradiction, discrepancy and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies.Health professionals are encouraged take fully into account when exercising clinical...
The ESC Guidelines represent the views of and were arrived at after careful consideration available evidence time they written.Health professionals are encouraged to take them fully into account when exercising their clinical judgement.The guidelines do not, however, override individual responsibility health make appropriate decisions in circumstances
Uncontrolled studies suggested that aerosolized iloprost, a stable analogue of prostacyclin, causes selective pulmonary vasodilatation and improves hemodynamics exercise capacity in patients with hypertension.
The role of fibrinolytic therapy in patients with intermediate-risk pulmonary embolism is controversial.In a randomized, double-blind trial, we compared tenecteplase plus heparin placebo normotensive embolism. Eligible had right ventricular dysfunction on echocardiography or computed tomography, as well myocardial injury indicated by positive test for cardiac troponin I T. primary outcome was death hemodynamic decompensation (or collapse) within 7 days after randomization. main safety...
Pulmonary arterial hypertension is a life-threatening disease for which continuous intravenous prostacyclin has proven to be effective. However, this treatment requires permanent central venous catheter with the associated risk of serious complications such as sepsis, thromboembolism, or syncope. Treprostinil, stable analogue, can administered by subcutaneous infusion, avoiding these risks. We conducted 12-week, double-blind, placebo-controlled multicenter trial in 470 patients pulmonary...
Current therapies for pulmonary arterial hypertension have been adopted on the basis of short-term trials with exercise capacity as primary end point. We assessed efficacy macitentan, a new dual endothelin-receptor antagonist, using point morbidity and mortality in long-term trial.We randomly assigned patients symptomatic to receive placebo once daily, macitentan at once-daily dose 3 mg, or 10 mg. Stable use oral inhaled therapy hypertension, other than antagonists, was allowed study entry....
Riociguat, a soluble guanylate cyclase stimulator, has been shown in phase 2 trial to be beneficial the treatment of pulmonary arterial hypertension.In this 3, double-blind study, we randomly assigned 443 patients with symptomatic hypertension receive placebo, riociguat individually adjusted doses up 2.5 mg three times daily (2.5 mg-maximum group), or that were capped at 1.5 (1.5 group). The group was included for exploratory purposes, and data from analyzed descriptively. Patients who...
Background— Treatment options for pulmonary arterial hypertension target the prostacyclin, endothelin, or nitric oxide pathways. Tadalafil, a phosphodiesterase type-5 inhibitor, increases cGMP, final mediator in pathway. Methods and Results— In this 16-week, double-blind, placebo-controlled study, 405 patients with (idiopathic associated), either treatment-naive on background therapy endothelin receptor antagonist bosentan, were randomized to placebo tadalafil 2.5, 10, 20, 40 mg orally once...
Background— Ambrisentan is a propanoic acid–based, A-selective endothelin receptor antagonist for the once-daily treatment of pulmonary arterial hypertension. Methods and Results— in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study 1 2 (ARIES-1 ARIES-2) were concurrent, double-blind, placebo-controlled studies that randomized 202 192 patients with hypertension, respectively, to placebo or ambrisentan (ARIES-1, 5 10 mg; ARIES-2, 2.5...
The Task Force has classified and ranked the usefulness or efficacy of recommended procedure and/or treatments Level Evidence as indicated in tables below: Classes RecommendationsClass I general agreement that a given diagnostic procedure/treatment is beneficial, useful effective; Class II Conflicting evidence divergence opinion about usefulness/efficacy treatment; IIa Weight evidence/opinion favour usefulness/efficacy; IIb Usefulness/efficacy less well established by evidence/opinion; III...
Data on the effect of initial combination therapy with ambrisentan and tadalafil long-term outcomes in patients pulmonary arterial hypertension are scarce.In this event-driven, double-blind study, we randomly assigned, a 2:1:1 ratio, participants World Health Organization functional class II or III symptoms who had not previously received treatment to receive 10 mg plus 40 (combination-therapy group), placebo (ambrisentan-monotherapy (tadalafil-monotherapy all administered once daily. The...
In a phase 2 trial, selexipag, an oral selective IP prostacyclin-receptor agonist, was shown to be beneficial in the treatment of pulmonary arterial hypertension.In this event-driven, 3, randomized, double-blind, placebo-controlled we randomly assigned 1156 patients with hypertension receive placebo or selexipag individualized doses (maximum dose, 1600 μg twice daily). Patients were eligible for enrollment if they not receiving stable dose endothelin-receptor antagonist, phosphodiesterase...
Abstract Aims To evaluate the impact of COVID-19 pandemic on patient admissions to Italian cardiac care units (CCUs). Methods and Results We conducted a multicentre, observational, nationwide survey collect data for acute myocardial infarction (AMI) at CCUs throughout 1 week period during outbreak, compared with equivalent in 2019. observed 48.4% reduction AMI 2019 (P < 0.001). The was significant both ST-segment elevation [STEMI; 26.5%, 95% confidence interval (CI) 21.7–32.3; P =...